NCT04205227
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on treatment with an anti-PD1/L1 monoclonal antibody (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies – see trial for details
Exclusions: Patients with known active CNS metastases and/or leptomeningeal disease that require treatment – see trial for details
https://ClinicalTrials.gov/show/NCT04205227